Correvio Pharma Corp (COM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- GDPH66500D
- Pages: 66
- November 2018
- Total Views:1154
- Region : North America
- GlobalData
- Equity Research Report
Details
Summary
Correvio Pharma Corp(Correvio) formerly known as Cardiome Pharma Corp, is a specialty pharmaceutical company, which develops and commercializes therapies for the treatment and prevention of cardiovascular diseases. The company's product portfolio includes two marketed products: Brinavess, for the rapid conversion of recent onset atrial fibrillation (AF) to sinus rhythm in adults; and Aggrastat, a GP IIb/IIIa inhibitor used for the treatment of acute coronary syndrome (ACS). Correvio has collaborations with other pharmaceutical companies to commercialize its products. It has operational presence with offices located in Canada, the US, Switzerland and the UK. Correvio is headquartered in Vancouver, British Columbia, Canada.
Correvio Pharma Corp (COM)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table Of Content
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Correvio Pharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Correvio Pharma Corp, Medical Devices Deals, 2012 to YTD 2018 10
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
Evotec and Artesian Therapeutics Enter into Agreement 13
Cardiome Pharma Enters into Agreement with Chong Kun Dang for BRINAVESS 14
Cardiome Pharma Enters into Agreement with Mitsubishi Tanabe Pharma Europe 15
Cardiome Pharma Enters into Commercialization Agreement with AOP Orphan Pharma 16
Cardiome Pharma Enters into Agreement with Eddingpharm to Develop and Commercialize Brinavess 17
Cardiome Pharma Enters into Co-Marketing Agreement with Aspen Pharma for Brinavess 18
Correvio International Enters into Distribution Agreement with Eurolab Especialidades for Brinavess 19
Cardiome Pharma Enters into Commercialization Agreement with AOP Orphan Pharma for Aggrastat 20
Cardiome Pharma Enters Into Commercialization Agreement With UDG Healthcare For Brinavess In Ireland 21
Cardiome Enters Into Commercialization Agreement With Algorithm For Brinavess 22
Cardiome Pharma Enters Into Commercialization Agreement With Tzamal Medical For Brinavess 23
Cardiome Pharma Enters Into Commercialization Agreement With AOP Orphan Pharma For Brinavess 24
Cardiome Pharma Enters Into Co-Marketing Agreement With Merck For Brinavess 25
Licensing Agreements 26
ZAO Firma Enters into Licensing Agreement with Correvio 26
Correvio International Enters into Licensing Agreement with ATCO Laboratories 27
Cardiome Pharma Enters into Licensing Agreement with Basilea Pharma 28
Tzamal Medical Enters into Licensing Agreement with Cardiome Pharma 29
Cardiome Enters into Licensing Agreement with Allergan for XYDALBA 30
Eddingpharm Enters into Licensing Agreement with Correvio International 31
SteadyMed Enters into Licensing Agreement with Cardiome Pharma 32
Equity Offering 33
Correvio Pharma to Raise up to USD30 Million in Public Offering of Shares 33
Correvio Pharma Plans to Raise up to USD250 Million in Public Offering of Securities 34
Cardiome Pharma Raises USD34.5 Million in Public Offering of Shares 35
Cardiome Pharma to Raise up to USD20 Million in Private Placement of Shares 37
Cardiome Pharma Raises USD23 Million in Public Offering of Shares 39
Cardiome Pharma Completes Public Offering Of Shares For USD 13.7 Million 41
Acquisition 43
Cipher Pharma Acquires Cardiome Pharma for USD19.5 Million 43
Cardiome Pharma Acquires Correvio, Cardiovascular Products Provider 45
CarCor Investment Acquires 16.6% Stake In Cardiome Pharma 46
Correvio Pharma Corp-Key Competitors 47
Correvio Pharma Corp-Key Employees 48
Correvio Pharma Corp-Locations And Subsidiaries 49
Head Office 49
Other Locations & Subsidiaries 49
Recent Developments 50
Financial Announcements 50
Aug 14, 2018: Correvio announces second quarter 2018 financial results 50
May 15, 2018: Correvio Announces First Quarter 2018 Financial Results 52
Mar 13, 2018: Cardiome Reports Fourth Quarter and Full Year 2017 Financial Results 54
Nov 14, 2017: Cardiome Reports Third Quarter 2017 Financial Results 56
Aug 08, 2017: Cardiome Reports Second Quarter 2017 Financial Results 58
May 15, 2017: Cardiome Reports First Quarter 2017 Financial Results 60
Mar 07, 2017: Cardiome Reports Fourth Quarter and Full Year 2016 Financial Results 61
Corporate Communications 63
May 16, 2017: Cardiome Reports Changes To Senior Management Team 63
Other Significant Developments 64
May 17, 2018: Correvio Pharma Formerly Cardiome Pharma, Announces Stock Ticker Symbol Change to CORV 64
May 10, 2018: Cardiome Announces Results From Annual and Special Meeting of Shareholders and Timing For First Quarter 2018 Financial Results Conference Call 65
Appendix 66
Methodology 66
About GlobalData 66
Contact Us 66
Disclaimer 66
List Of Figure
List of Figures
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Correvio Pharma Corp, Medical Devices Deals, 2012 to YTD 2018 10
List Of Table
List of Tables
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Correvio Pharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Correvio Pharma Corp, Deals By Therapy Area, 2012 to YTD 2018 9
Correvio Pharma Corp, Medical Devices Deals, 2012 to YTD 2018 10
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Evotec and Artesian Therapeutics Enter into Agreement 13
Cardiome Pharma Enters into Agreement with Chong Kun Dang for BRINAVESS 14
Cardiome Pharma Enters into Agreement with Mitsubishi Tanabe Pharma Europe 15
Cardiome Pharma Enters into Commercialization Agreement with AOP Orphan Pharma 16
Cardiome Pharma Enters into Agreement with Eddingpharm to Develop and Commercialize Brinavess 17
Cardiome Pharma Enters into Co-Marketing Agreement with Aspen Pharma for Brinavess 18
Correvio International Enters into Distribution Agreement with Eurolab Especialidades for Brinavess 19
Cardiome Pharma Enters into Commercialization Agreement with AOP Orphan Pharma for Aggrastat 20
Cardiome Pharma Enters Into Commercialization Agreement With UDG Healthcare For Brinavess In Ireland 21
Cardiome Enters Into Commercialization Agreement With Algorithm For Brinavess 22
Cardiome Pharma Enters Into Commercialization Agreement With Tzamal Medical For Brinavess 23
Cardiome Pharma Enters Into Commercialization Agreement With AOP Orphan Pharma For Brinavess 24
Cardiome Pharma Enters Into Co-Marketing Agreement With Merck For Brinavess 25
ZAO Firma Enters into Licensing Agreement with Correvio 26
Correvio International Enters into Licensing Agreement with ATCO Laboratories 27
Cardiome Pharma Enters into Licensing Agreement with Basilea Pharma 28
Tzamal Medical Enters into Licensing Agreement with Cardiome Pharma 29
Cardiome Enters into Licensing Agreement with Allergan for XYDALBA 30
Eddingpharm Enters into Licensing Agreement with Correvio International 31
SteadyMed Enters into Licensing Agreement with Cardiome Pharma 32
Correvio Pharma to Raise up to USD30 Million in Public Offering of Shares 33
Correvio Pharma Plans to Raise up to USD250 Million in Public Offering of Securities 34
Cardiome Pharma Raises USD34.5 Million in Public Offering of Shares 35
Cardiome Pharma to Raise up to USD20 Million in Private Placement of Shares 37
Cardiome Pharma Raises USD23 Million in Public Offering of Shares 39
Cardiome Pharma Completes Public Offering Of Shares For USD 13.7 Million 41
Cipher Pharma Acquires Cardiome Pharma for USD19.5 Million 43
Cardiome Pharma Acquires Correvio, Cardiovascular Products Provider 45
CarCor Investment Acquires 16.6% Stake In Cardiome Pharma 46
Correvio Pharma Corp, Key Competitors 47
Correvio Pharma Corp, Key Employees 48
Correvio Pharma Corp, Subsidiaries 49
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Products
Correvio Pharma Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Company Profile
Company Profile Title
Summary
Correvio Pharma Corp(Correvio) formerly known as Cardiome Pharma Corp, is a specialty pharmaceutical company, which develops and commercializes therapies for the treatment and prevention of cardiovascular diseases. The company's product portfolio includes two marketed products: Brinavess, for the rapid conversion of recent onset atrial fibrillation (AF) to sinus rhythm in adults; and Aggrastat, a GP IIb/IIIa inhibitor used for the treatment of acute coronary syndrome (ACS). Correvio has collaborations with other pharmaceutical companies to commercialize its products. It has operational presence with offices located in Canada, the US, Switzerland and the UK. Correvio is headquartered in Vancouver, British Columbia, Canada.
Correvio Pharma Corp (COM)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Scope
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Correvio Pharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Correvio Pharma Corp, Medical Devices Deals, 2012 to YTD 2018 10
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
Evotec and Artesian Therapeutics Enter into Agreement 13
Cardiome Pharma Enters into Agreement with Chong Kun Dang for BRINAVESS 14
Cardiome Pharma Enters into Agreement with Mitsubishi Tanabe Pharma Europe 15
Cardiome Pharma Enters into Commercialization Agreement with AOP Orphan Pharma 16
Cardiome Pharma Enters into Agreement with Eddingpharm to Develop and Commercialize Brinavess 17
Cardiome Pharma Enters into Co-Marketing Agreement with Aspen Pharma for Brinavess 18
Correvio International Enters into Distribution Agreement with Eurolab Especialidades for Brinavess 19
Cardiome Pharma Enters into Commercialization Agreement with AOP Orphan Pharma for Aggrastat 20
Cardiome Pharma Enters Into Commercialization Agreement With UDG Healthcare For Brinavess In Ireland 21
Cardiome Enters Into Commercialization Agreement With Algorithm For Brinavess 22
Cardiome Pharma Enters Into Commercialization Agreement With Tzamal Medical For Brinavess 23
Cardiome Pharma Enters Into Commercialization Agreement With AOP Orphan Pharma For Brinavess 24
Cardiome Pharma Enters Into Co-Marketing Agreement With Merck For Brinavess 25
Licensing Agreements 26
ZAO Firma Enters into Licensing Agreement with Correvio 26
Correvio International Enters into Licensing Agreement with ATCO Laboratories 27
Cardiome Pharma Enters into Licensing Agreement with Basilea Pharma 28
Tzamal Medical Enters into Licensing Agreement with Cardiome Pharma 29
Cardiome Enters into Licensing Agreement with Allergan for XYDALBA 30
Eddingpharm Enters into Licensing Agreement with Correvio International 31
SteadyMed Enters into Licensing Agreement with Cardiome Pharma 32
Equity Offering 33
Correvio Pharma to Raise up to USD30 Million in Public Offering of Shares 33
Correvio Pharma Plans to Raise up to USD250 Million in Public Offering of Securities 34
Cardiome Pharma Raises USD34.5 Million in Public Offering of Shares 35
Cardiome Pharma to Raise up to USD20 Million in Private Placement of Shares 37
Cardiome Pharma Raises USD23 Million in Public Offering of Shares 39
Cardiome Pharma Completes Public Offering Of Shares For USD 13.7 Million 41
Acquisition 43
Cipher Pharma Acquires Cardiome Pharma for USD19.5 Million 43
Cardiome Pharma Acquires Correvio, Cardiovascular Products Provider 45
CarCor Investment Acquires 16.6% Stake In Cardiome Pharma 46
Correvio Pharma Corp-Key Competitors 47
Correvio Pharma Corp-Key Employees 48
Correvio Pharma Corp-Locations And Subsidiaries 49
Head Office 49
Other Locations & Subsidiaries 49
Recent Developments 50
Financial Announcements 50
Aug 14, 2018: Correvio announces second quarter 2018 financial results 50
May 15, 2018: Correvio Announces First Quarter 2018 Financial Results 52
Mar 13, 2018: Cardiome Reports Fourth Quarter and Full Year 2017 Financial Results 54
Nov 14, 2017: Cardiome Reports Third Quarter 2017 Financial Results 56
Aug 08, 2017: Cardiome Reports Second Quarter 2017 Financial Results 58
May 15, 2017: Cardiome Reports First Quarter 2017 Financial Results 60
Mar 07, 2017: Cardiome Reports Fourth Quarter and Full Year 2016 Financial Results 61
Corporate Communications 63
May 16, 2017: Cardiome Reports Changes To Senior Management Team 63
Other Significant Developments 64
May 17, 2018: Correvio Pharma Formerly Cardiome Pharma, Announces Stock Ticker Symbol Change to CORV 64
May 10, 2018: Cardiome Announces Results From Annual and Special Meeting of Shareholders and Timing For First Quarter 2018 Financial Results Conference Call 65
Appendix 66
Methodology 66
About GlobalData 66
Contact Us 66
Disclaimer 66
List Of Figure
List of Figures
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Correvio Pharma Corp, Medical Devices Deals, 2012 to YTD 2018 10
List Of Table
List of Tables
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Correvio Pharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Correvio Pharma Corp, Deals By Therapy Area, 2012 to YTD 2018 9
Correvio Pharma Corp, Medical Devices Deals, 2012 to YTD 2018 10
Correvio Pharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Evotec and Artesian Therapeutics Enter into Agreement 13
Cardiome Pharma Enters into Agreement with Chong Kun Dang for BRINAVESS 14
Cardiome Pharma Enters into Agreement with Mitsubishi Tanabe Pharma Europe 15
Cardiome Pharma Enters into Commercialization Agreement with AOP Orphan Pharma 16
Cardiome Pharma Enters into Agreement with Eddingpharm to Develop and Commercialize Brinavess 17
Cardiome Pharma Enters into Co-Marketing Agreement with Aspen Pharma for Brinavess 18
Correvio International Enters into Distribution Agreement with Eurolab Especialidades for Brinavess 19
Cardiome Pharma Enters into Commercialization Agreement with AOP Orphan Pharma for Aggrastat 20
Cardiome Pharma Enters Into Commercialization Agreement With UDG Healthcare For Brinavess In Ireland 21
Cardiome Enters Into Commercialization Agreement With Algorithm For Brinavess 22
Cardiome Pharma Enters Into Commercialization Agreement With Tzamal Medical For Brinavess 23
Cardiome Pharma Enters Into Commercialization Agreement With AOP Orphan Pharma For Brinavess 24
Cardiome Pharma Enters Into Co-Marketing Agreement With Merck For Brinavess 25
ZAO Firma Enters into Licensing Agreement with Correvio 26
Correvio International Enters into Licensing Agreement with ATCO Laboratories 27
Cardiome Pharma Enters into Licensing Agreement with Basilea Pharma 28
Tzamal Medical Enters into Licensing Agreement with Cardiome Pharma 29
Cardiome Enters into Licensing Agreement with Allergan for XYDALBA 30
Eddingpharm Enters into Licensing Agreement with Correvio International 31
SteadyMed Enters into Licensing Agreement with Cardiome Pharma 32
Correvio Pharma to Raise up to USD30 Million in Public Offering of Shares 33
Correvio Pharma Plans to Raise up to USD250 Million in Public Offering of Securities 34
Cardiome Pharma Raises USD34.5 Million in Public Offering of Shares 35
Cardiome Pharma to Raise up to USD20 Million in Private Placement of Shares 37
Cardiome Pharma Raises USD23 Million in Public Offering of Shares 39
Cardiome Pharma Completes Public Offering Of Shares For USD 13.7 Million 41
Cipher Pharma Acquires Cardiome Pharma for USD19.5 Million 43
Cardiome Pharma Acquires Correvio, Cardiovascular Products Provider 45
CarCor Investment Acquires 16.6% Stake In Cardiome Pharma 46
Correvio Pharma Corp, Key Competitors 47
Correvio Pharma Corp, Key Employees 48
Correvio Pharma Corp, Subsidiaries 49
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products
Correvio Pharma Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Ask A Question
Our Team Will Assist You in What You Are Looking For
or 
: +91 98100 26150
: ankurgupta1984
Related Reports
Page 130 | 
December 2020
Page 130 | December 2020
Page 131 | November 2020
Page 95 | November 2020
Page 96 | August 2020